vs
LifeStance Health Group, Inc.（LFST）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是LifeStance Health Group, Inc.的1.9倍（$708.5M vs $382.2M），Medpace Holdings, Inc.净利率更高（19.1% vs 3.1%，领先16.0%），Medpace Holdings, Inc.同比增速更快（32.0% vs 17.4%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $46.6M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 12.8%）
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
LFST vs MEDP — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $382.2M | $708.5M |
| 净利润 | $11.7M | $135.1M |
| 毛利率 | — | — |
| 营业利润率 | 4.7% | 21.6% |
| 净利率 | 3.1% | 19.1% |
| 营收同比 | 17.4% | 32.0% |
| 净利润同比 | 264.1% | 15.5% |
| 每股收益（稀释后） | — | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $382.2M | $708.5M | ||
| Q3 25 | $363.8M | $659.9M | ||
| Q2 25 | $345.3M | $603.3M | ||
| Q1 25 | $333.0M | $558.6M | ||
| Q4 24 | $325.5M | $536.6M | ||
| Q3 24 | $312.7M | $533.3M | ||
| Q2 24 | $312.3M | $528.1M | ||
| Q1 24 | $300.4M | $511.0M |
| Q4 25 | $11.7M | $135.1M | ||
| Q3 25 | $1.1M | $111.1M | ||
| Q2 25 | $-3.8M | $90.3M | ||
| Q1 25 | $709.0K | $114.6M | ||
| Q4 24 | $-7.1M | $117.0M | ||
| Q3 24 | $-6.0M | $96.4M | ||
| Q2 24 | $-23.3M | $88.4M | ||
| Q1 24 | $-21.1M | $102.6M |
| Q4 25 | 4.7% | 21.6% | ||
| Q3 25 | 2.0% | 21.5% | ||
| Q2 25 | -0.9% | 20.9% | ||
| Q1 25 | 0.5% | 20.3% | ||
| Q4 24 | 0.3% | 23.4% | ||
| Q3 24 | 0.0% | 21.1% | ||
| Q2 24 | -5.1% | 19.9% | ||
| Q1 24 | -5.6% | 20.4% |
| Q4 25 | 3.1% | 19.1% | ||
| Q3 25 | 0.3% | 16.8% | ||
| Q2 25 | -1.1% | 15.0% | ||
| Q1 25 | 0.2% | 20.5% | ||
| Q4 24 | -2.2% | 21.8% | ||
| Q3 24 | -1.9% | 18.1% | ||
| Q2 24 | -7.5% | 16.7% | ||
| Q1 24 | -7.0% | 20.1% |
| Q4 25 | — | $4.65 | ||
| Q3 25 | — | $3.86 | ||
| Q2 25 | — | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | — | $3.01 | ||
| Q2 24 | — | $2.75 | ||
| Q1 24 | — | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $248.6M | $497.0M |
| 总债务越低越好 | $282.8M | — |
| 股东权益账面价值 | $1.5B | $459.1M |
| 总资产 | $2.2B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
| Q4 25 | $248.6M | $497.0M | ||
| Q3 25 | $203.9M | $285.4M | ||
| Q2 25 | $188.9M | $46.3M | ||
| Q1 25 | $134.3M | $441.4M | ||
| Q4 24 | $154.6M | $669.4M | ||
| Q3 24 | $102.6M | $656.9M | ||
| Q2 24 | $87.0M | $510.9M | ||
| Q1 24 | $49.5M | $407.0M |
| Q4 25 | $282.8M | — | ||
| Q3 25 | $284.6M | — | ||
| Q2 25 | $286.4M | — | ||
| Q1 25 | $288.2M | — | ||
| Q4 24 | $290.0M | — | ||
| Q3 24 | $287.3M | — | ||
| Q2 24 | $288.0M | — | ||
| Q1 24 | $288.8M | — |
| Q4 25 | $1.5B | $459.1M | ||
| Q3 25 | $1.5B | $293.6M | ||
| Q2 25 | $1.5B | $172.4M | ||
| Q1 25 | $1.5B | $593.6M | ||
| Q4 24 | $1.4B | $825.5M | ||
| Q3 24 | $1.4B | $881.4M | ||
| Q2 24 | $1.4B | $763.6M | ||
| Q1 24 | $1.4B | $671.5M |
| Q4 25 | $2.2B | $2.0B | ||
| Q3 25 | $2.1B | $1.8B | ||
| Q2 25 | $2.1B | $1.6B | ||
| Q1 25 | $2.1B | $1.9B | ||
| Q4 24 | $2.1B | $2.1B | ||
| Q3 24 | $2.1B | $2.1B | ||
| Q2 24 | $2.1B | $1.9B | ||
| Q1 24 | $2.1B | $1.8B |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.20× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.6M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $46.6M | $188.1M |
| 自由现金流率自由现金流/营收 | 12.2% | 26.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.6% |
| 现金转化率经营现金流/净利润 | 4.93× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $110.0M | $681.9M |
8季度趋势，按日历期对齐
| Q4 25 | $57.6M | $192.7M | ||
| Q3 25 | $27.3M | $246.2M | ||
| Q2 25 | $64.4M | $148.5M | ||
| Q1 25 | $-3.1M | $125.8M | ||
| Q4 24 | $62.3M | $190.7M | ||
| Q3 24 | $22.7M | $149.1M | ||
| Q2 24 | $44.1M | $116.4M | ||
| Q1 24 | $-21.8M | $152.7M |
| Q4 25 | $46.6M | $188.1M | ||
| Q3 25 | $17.0M | $235.5M | ||
| Q2 25 | $56.6M | $142.4M | ||
| Q1 25 | $-10.3M | $115.8M | ||
| Q4 24 | $56.0M | $183.0M | ||
| Q3 24 | $17.7M | $138.5M | ||
| Q2 24 | $39.0M | $103.5M | ||
| Q1 24 | $-26.9M | $147.2M |
| Q4 25 | 12.2% | 26.6% | ||
| Q3 25 | 4.7% | 35.7% | ||
| Q2 25 | 16.4% | 23.6% | ||
| Q1 25 | -3.1% | 20.7% | ||
| Q4 24 | 17.2% | 34.1% | ||
| Q3 24 | 5.7% | 26.0% | ||
| Q2 24 | 12.5% | 19.6% | ||
| Q1 24 | -9.0% | 28.8% |
| Q4 25 | 2.9% | 0.6% | ||
| Q3 25 | 2.8% | 1.6% | ||
| Q2 25 | 2.2% | 1.0% | ||
| Q1 25 | 2.2% | 1.8% | ||
| Q4 24 | 1.9% | 1.4% | ||
| Q3 24 | 1.6% | 2.0% | ||
| Q2 24 | 1.6% | 2.4% | ||
| Q1 24 | 1.7% | 1.1% |
| Q4 25 | 4.93× | 1.43× | ||
| Q3 25 | 25.34× | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | -4.36× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LFST
暂无分部数据
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
